Project Grant R01AG085666
- This $487,574 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to elucidate the role of reactive astrocytes in the propagation and clearance of tau protein in Alzheimer's disease. The 5-year project, conducted by the General Hospital Corporation (doing business as Massachusetts General Hospital), aims to investigate how upregulation of the astrocyte marker GFAP may ameliorate the trans-synaptic spread of pathogenic phospho-tau species...
- This $461,146 federal project grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Yale University supports research to investigate the disruption of astrocytes, a key cell type in the brain, and its relationship to the development of Alzheimer's disease (AD) in animal models. The project aims to utilize novel imaging techniques to longitudinally track changes in astrocytic and neuromodulatory signaling across the cortex in awake behaving animals over the 2-year...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $522,500.00 to The Salk Institute for Biological Studies to conduct research aimed at understanding the role of astrocytes, a type of non-neuronal brain cell, in contributing to age-related motor and cognitive decline. The key objectives are to determine if the transcription factor STAT1 drives age-related changes in cerebellar astrocytes, and whether modulating STAT1 can prevent or rescue...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will investigate the role of glial fibrillary acidic protein (GFAP) upregulation in reactive astrocytes and its impact on tripartite excitatory synapses in a tauopathy mouse model of Alzheimer's disease. Specifically, the $452,550 award to The General Hospital Corporation (dba Massachusetts General Hospital) will overexpress GFAP in astrocytes and blunt GFAP upregulation to evaluate changes in the...
- This $427,625 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866). The grant was awarded to The Washington University in St. Louis to support research evaluating novel transcription factors that regulate astrocyte identity, reactivity, and their roles in the pathogenesis of Alzheimer's disease (AD) and Parkinson's disease (PD). The research aims to systematically evaluate 10 candidate transcription factors identified...
- This Project Grant award of $758,744 from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to investigate the mechanistic link between tau signaling and blood-brain barrier dysfunction in Alzheimer's disease (AD). The objective is to establish a mechanism-based intervention targeting amyloid-beta and tau to repair blood-brain barrier dysfunction and slow cognitive decline in AD models. The research will be conducted by the University of Kentucky Research...
- This $3.6 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund research at the Icahn School of Medicine at Mount Sinai directed at understanding the role of glial cell interactions surrounding amyloid plaques in the progression of Alzheimer's disease. As part of the Aging Research program (CFDA 93.866), the three-year award will support investigation of how deletion of the Plexin-B1 gene impacts glial network formation and the...
- This Project Grant award from the National Institutes of Health's Aging Research program (CFDA 93.866) will support research to identify early transcriptional and pathological changes in brain regions vulnerable to Alzheimer's disease (AD). The $459,076 award, granted to Trustees of Boston University, will use single-nucleus RNA sequencing and targeted mass spectrometry to profile cell type-specific gene expression and tau/amyloid beta proteoforms in the transentorhinal cortex, entorhinal...
- This $2,957,210 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the role of CD44-expressing astrocytes in Alzheimer's disease (AD) pathology. The award supports a 4-year research project undertaken by the Trustees of Columbia University in New York. The key objectives are to: 1) elucidate the signaling mechanisms by which CD44 alters astrocyte phenotype and function in vitro, and 2) investigate the impact of astrocytic CD44 on...
- The National Institute on Aging (NIA), through the Aging Research Federal Grant Program (CFDA 93.866), awarded a $500,000 Project Grant to T-Neuro Inc. to confirm the use of aberrant T cells as an amyloid-independent blood biomarker for potentially earlier diagnosis and tracking the progression of Alzheimer's disease (AD). The award period is from August 1, 2025 to July 31, 2026. The project aims to demonstrate that alterations in age-related cytolytic (CD8) T cells can impact AD pathology...
ATYPICAL ASTROCYTES IN AGING AND ALZHEIMER'S DISEASE - SUMMARY. ASTROCYTES CONTROL NEUROTRANSMISSION, CONTRIBUTE TO THE BLOOD-BRAIN-BARRIER (BBB), AND SHAPE INFLAMMATORY RESPONSES. IN HEALTHY AGING, MANY ASPECTS OF ASTROCYTE FUNCTION ARE ALTERED BUT WHAT DRIVES AGING-RELATED CHANGES IS NOT WELL UNDERSTOOD. HERE, WE PRESENT EXCITING PRELIMINARY DATA THAT DURING NORMAL AGING, ASTROCYTES TAKE ON A NOVEL PHENOTYPE IN WHICH PROGRESSIVELY MORE ASTROCYTES LOSE THE EXPRESSION OF KEY FUNCTIONAL PROTEINS. WE REFER TO THESE AS ATYPICAL ASTROCYTES (ATAS). ATAS LACK EXPRESSION OF EXCITATORY AMINO ACID TRANSPORTERS (EAATS: GLT-1 AND GLAST), THAT REMOVE GLUTAMATE FROM THE EXTRACELLULAR SPACE, KIR4.1, WHICH MEDIATES EXTRACELLULAR POTASSIUM (K+) BUFFERING, AND AQUAPORIN-4 (AQP-4), WHICH HELPS CLEAR A FROM THE BRAIN. THESE CHANGES OCCUR ON A CELL-BY-CELL BASIS, WITH INDIVIDUAL ASTROCYTES EXPRESSING MINIMAL EAAT, KIR4.1, AND AQP-4, WHILE NEIGHBORING ASTROCYTES REMAIN NORMAL. ATAS DO NOT APPEAR TO BE REACTIVE ASTROCYTES AS THEY LACK ELEVATED GFAP EXPRESSION AND HAVE NORMAL ASTROCYTE MORPHOLOGY. PRELIMINARY IGLUSNFR AND ASTROCYTE ELECTROPHYSIOLOGY DATA SUGGEST THAT GLUTAMATE AND K+ HOMEOSTASIS IS COMPROMISED IN AREAS WHERE ATAS ARE ABUNDANT. WHAT CAUSES ATA TO FORM IS NOT KNOWN, BUT PUBLISHED AND PRELIMINARY STUDIES SUGGEST ATAS ARE ASSOCIATED WITH VASCULAR STRUCTURES AND ARE FOUND IN AREAS OF BLOOD-BRAIN-BARRIER (BBB) COMPROMISE. OUR PRELIMINARY DATA ALSO SUGGESTS THAT ATAS ARE FOUND IN THE AGING HUMAN BRAIN AND ARE MORE ABUNDANT IN THE APPNL-G-F MODEL OF AD, AS COMPARED TO WT MICE. THEREFORE, WE HYPOTHESIZE THAT AGE-ASSOCIATED VASCULAR DYSFUNCTION DRIVES THE FORMATION OF ATAS, DISRUPTING ASTROCYTE FUNCTION AND CONTRIBUTING TO SYNAPTIC AND AD-RELATED PATHOLOGY. ASTROCYTE DYSFUNCTION OCCURS LATE IN AD PROGRESSION, BUT HOW ASTROCYTES CONTRIBUTE TO EARLY AD PATHOLOGY IS NOT WELL UNDERSTOOD. WE SUSPECT ATAS OCCUR EARLY IN AD PROGRESSION AND CONTRIBUTE TO DIVERSE AD DISEASE MECHANISMS. EVIDENCE SUPPORTS THAT ABERRANT GLUTAMATE SIGNALING CONTRIBUTES TO AD PROGRESSION. DISRUPTED AQP-4 EXPRESSION IS A HALLMARK OF AD AND ASSOCIATED WITH REDUCED A CLEARANCE. VASCULAR DYSFUNCTION IS AN AD RISK FACTOR AND ASTROCYTES CONTRIBUTE TO BBB INTEGRITY. TO EXAMINE ATAS IN A MODEL OF AD, WE CHOSE THE APPNL-G-F MICE DUE TO EARLY ONSET OF ELEVATED SOLUBLE A AND PLAQUES OVERLAPPING WITH THE NORMAL DEVELOPMENT OF ATAS, WITHOUT APP OVEREXPRESSION. IF OUR HYPOTHESIS IS CORRECT, ATAS MAY BE A CENTRAL PLAYER IN AGING AND AD-RELATED PATHOLOGIES LINKING VASCULAR DYSFUNCTION TO SYNAPTIC AND A PATHOLOGY. IN THIS PROPOSAL WE WILL DETERMINE 1) WHAT ARE THE MOLECULAR AND CELLULAR PHENOTYPES OF ATAS IN THE AGING AND AD BRAIN?, 2) DO ATAS DISRUPT SYNAPTIC FUNCTION, IONIC HOMEOSTASIS, AND A HANDLING?, AND 3) DOES BBB DYSFUNCTION CONTRIBUTE TO THE GENERATION OF ATAS? WHEN COMPLETE, WE WILL KNOW THE MOLECULAR AND CELLULAR PROPERTIES OF AGE-ASSOCIATED ATAS, THEIR EFFECTS ON ASTROCYTE-MEDIATED HOMEOSTASIS, AND THEIR RELATIONSHIP WITH BBB DYSFUNCTION. IF ATAS MEDIATE ASTROCYTE-NEURON DYSFUNCTION CAUSED BY AGE-RELATED VASCULAR PATHOLOGY, IT WILL REPRESENT AN ENTIRELY NEW AVENUE TO PURSUE FOR TREATING AD AND OTHER AGE-RELATED NEUROLOGICAL DISEASE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $66.6k | 6/10/25 | ||
| Not listed | $749.5k | 4/1/25 | ||
| Not listed | $749.5k | 4/1/25 | ||
| Not listed | $854.9k | 5/14/24 | ||
| Not listed | $854.9k | 5/14/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
EP0246731S | University Of Massachusetts Medical School | Project Grant R01AG085666 | $130.4k | 6/26/25 | |
EP0244820S | University Of Alabama At Birmingham | Project Grant R01AG085666 | $41.3k | 5/29/25 |